Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 13/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30449882 | 0.90 | HTR2A (0.58) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL28070559 | 0.90 | HTR2A (0.58) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL989652 | 0.90 | HTR2A (0.58) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL14005994 | 0.87 | HTR2A (0.47) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL28852792 | 0.84 | HTR2A (0.53) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL13523868 | 0.82 | HTR2A (0.52) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL15662571 | 0.81 | MTNR1A (0.54) | HTR2AMTNR1AMTNR1B | |
| SCHEMBL13523869 | 0.79 | HTR2A (0.57) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL14005971 | 0.78 | HTR2A (0.56) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL3148273 | 0.78 | HTR2A (0.56) | HTR2AMTNR1AMTNR1BHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150525-A1 | NAPHTHYL(ETHYL) ACETAMIDES | Concert Pharmaceuticals Inc. (US) | 2010-02-10 | — | — | EP | disclosed |
| US-20100004340-A1 | NAPHTHYL(ETHYL) ACETAMIDES | CONCERT PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004340-A1 | NAPHTHYL(ETHYL) ACETAMIDES | CONCERT PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-7608737-B2 | Naphthyl(ethyl)acetamides | Concert Pharmaceuticasl Inc. (US) | 2009-10-27 | — | — | US | disclosed |
| WO-2008137461-A1 | NAPHTHYL(ETHYL) ACETAMIDES | CONCERT PHARMACEUTICALS INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20080280908-A1 | NAPHTHYL(ETHYL) ACETAMIDES | CONCERT PHARMACEUTICALS INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280991-A1 | SUBSTITUTED NAPHTHALENES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280908-A1 | NAPHTHYL(ETHYL) ACETAMIDES | AANAT, MTNR1A, TPH2 | HTR2A 4/4885MTNR1A 2/4885MTNR1B 5/4885 |
| US-20080280991-A1 | SUBSTITUTED NAPHTHALENES | MTNR1A, MTNR1B, TPH1 | HTR2A 6/4885MTNR1A 1/4885MTNR1B 2/4885 |
| US-20100004340-A1 | NAPHTHYL(ETHYL) ACETAMIDES | AANAT, MTNR1A, TPH2 | HTR2A 4/4885MTNR1A 2/4885MTNR1B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.